Competitive Technologies, Inc. (AMEX: CTT) $43M (MarketCap) Presents Calmare Pain Therapy Treatment at Symposium

Competitive Technologies Inc. presented The Calmare Pain Therapy Conference which began with keynote speaker and Calmare's inventor, Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, Italy. Prof. Marineo explained his "Scrambler Therapy," the technology and scientific basis for this revolutionary pain treatment method. Prof. Marineo provided an overview of the history of "electro-analgesia", emphasizing that his "Scrambler Therapy" was the first electro-analgesic methodology to exploit the central nervous system's C-fibers to remodel and eliminate a patient's pain.

Throughout the day, physicians from the Boston Foundation for Sight, the University of Miami, the University of Wisconsin, and Calmar Pain Relief, LLC, presented evidence-based patient case studies developed from their use of this innovative technology to treat various types of chronic pain. Typically, the patient's pain had been resistant to other treatment methodologies, including powerful narcotic painkillers, with associated adverse side effects.

"I have come to believe that no one should live in pain," stated Stephen J. D'Amato, MD, FACEP; Medical Director, Calmar Pain Relief, LLC; Clinical Assistant Professor of Medicine, Boston University School of Medicine, and Medical Staff, Roger Williams Medical Center; after sharing several evidence-based case studies of patients successfully treated in his Rhode Island clinic. Suffering from chronic and debilitating neuropathic pain, the patients discussed all had their pain relieved with Calmare treatments. "We owe it to our patients to treat them with dignity in attempting to ease their pain. At the very least we should do no harm. This non-invasive treatment does no harm."

"We are privileged and pleased that these doctors have attested to the effectiveness of our Calmare Pain Therapy Treatment by sharing their evidence-based patient successes with the community of physicians attending our symposium," said John B. Nano, CTT's Chairman, President and CEO. "Having Prof. Marineo discuss this innovative technology has provided a unique perspective for physicians to gain a deeper understanding of how the device functions and the treatment's efficacy in relieving patients' pain. We are encouraged by the positive response of this community of medical professionals to both Prof. Marineo and the physicians who presented their evidence-based patient case studies."

With recent media coverage focusing on the negative side effects of morphine and other powerful painkillers, the Calmare device offers physicians an effective and cost-effective alternative for treating high intensity oncologic and neuropathic pain, including pain resistant to opioids and other treatment methodologies. The Calmare Pain Therapy Treatment, with US FDA clearance and European Union CE Certification for sales, is a prime example of CTT's strategy to connect clinical science to patient care.